During this virtual event, Esther McNamara, ILC's Senior Health Policy Lead, presents the Trial and error report’s findings and recommendations. A panel of five experts respond to the report and discuss how improved age diversity will benefit patients of all ages.
Call Girls Rishikesh Just Call 9667172968 Top Class Call Girl Service Available
Launching Trial and error: Supporting age diversity in clinical trials
1. Launching Trial and error:
Supporting age diversity in
clinical trials
Join the conversation: @ilcuk
#TrialandError
2. @ilcuk
#TrialandError
Launching Trial and error: Supporting age
diversity in clinical trials
Dave Valacer MD
Regor Pharmaceuticals
regor.com
Esther McNamara
ILC-UK
@ilcuk
Pol Vandenbroucke
Global Longevity Council
ILC Trustee
@ilcuk
Mike Keens
Thompson Street Capital
Partners
@keensmike
Rosemary Lakeru
Acorn IQ
acorniq.co
Chair: Emma Thorp
RBW Consulting
@RBWConsulting
Professor Miles Witham
Newcastle University
@OlderTrialsProf
@UniofNewcastle
5. Discussion panel
Mike Keens, Operating Executive, Thompson Street Capital Partners
Rosemary Lakeru, Founder & CEO, Acorn IQ
Dave Valacer MD, Chief Medical Officer, Regor Pharmaceuticals
Professor Miles Witham, Professor of Trials for Older People, Newcastle
University
6. Esther McNamara
Project Lead & Senior Health Policy Lead
ILC-UK
esthermcnamara@ilcuk.org.uk
Join the conversation: @ilcuk
#TrialandError
7. We found that the key barriers to age parity in clinical trial cohorts are:
• Cost
• ‘Clean’ data
• Arbitrary exclusions
• Practical considerations
Some great strides are being taken towards age diversity, but progress is
inconsistent with the needs of ageing populations.
Key findings
8. Our recommendations
Co-produce new guidelines to replace
ICH-E7
Increase incentives for age-diverse
cohorts
Prioritise gathering age-related data in
all trials
Introduce ‘gold standard’ for inclusive
trials
Expand existing D&I initiatives to
include age
Appoint diversity champions in all trials
Invest in technological advances to
support participation
Ringfence funding for consistent patient
and public involvement
9. Recommendation #1
New guidelines to replace ICH-E7
These would be co-produced by regulators, pharmaceutical
companies, academic researchers, and other stakeholders.
Join the conversation: @ilcuk
#TrialandError
11. Recommendation #3
Researchers and companies should prioritise gathering age-
specific data across all trials.
Join the conversation: @ilcuk
#TrialandError
12. Recommendation #4
Development of consistent Patient and Public Involvement (PPI)
infrastructure across the sector.
Join the conversation: @ilcuk
#TrialandError
15. Upcoming events
Healthy ageing:
Priorities for the G20
in India
Webinar
Tuesday 25 April
G7 high-level side
events in Japan:
Healthy ageing and
prevention
10 May - Niigata
18 May - Hiroshima
Global launch of the
Healthy Ageing and
Prevention Index - 76th
World Health Assembly
Geneva, Switzerland
Tuesday 23 May